Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3903 ARTÍCULOS , VIENDO DEL 721 AL 735

Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review

Rivera-Oliver M, Díaz-Ríos M.

Life Sci. 2014 Apr 17;101(1-2):1-9. doi: 10.1016/j.lfs.2014.01.083. Epub 2014 Feb 13.

Freezing of gait in Parkinson's disease: current treatments and the potential role for cognitive training

Walton CC, Shine JM, Mowszowski L, Naismith SL, Lewis SJ.

Restor Neurol Neurosci. 2014;32(3):411-22. doi: 10.3233/RNN-130370.

Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients

Politis M, Wu K, Loane C, Brooks DJ, Kiferle L, Turkheimer FE, Bain P, Molloy S, Piccini P.

J Clin Invest. 2014 Mar;124(3):1340-9. doi: 10.1172/JCI71640. Epub 2014 Feb 17.

Glucocerebrosidase is shaking up the synucleinopathies

Siebert M, Sidransky E, Westbroek W.

Brain. 2014 May;137(Pt 5):1304-22. doi: 10.1093/brain/awu002. Epub 2014 Feb 14.

The T-type calcium channel as a new therapeutic target for Parkinson's disease

Yang YC, Tai CH, Pan MK, Kuo CC.

Pflugers Arch. 2014 Apr;466(4):747-55. doi: 10.1007/s00424-014-1466-6. Epub 2014 Feb 18.

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy

Tolosa E, Litvan I, Höglinger GU, Burn D, Lees A, Andrés MV, Gómez-Carrillo B, León T, Del Ser T; TAUROS Investigators.

Mov Disord. 2014 Apr;29(4):470-8. doi: 10.1002/mds.25824. Epub 2014 Feb 14.

Reversible dopamine transporter reduction in drug-induced Parkinsonism

Cilia R, Marotta G, Belletti A, Siri C, Pezzoli G.

Mov Disord. 2014 Apr;29(4):575-7. doi: 10.1002/mds.25828. Epub 2014 Feb 14.

The effect of deep brain stimulation randomized by site on balance in Parkinson's disease

St George RJ, Carlson-Kuhta P, Nutt JG, Hogarth P, Burchiel KJ, Horak FB.

Mov Disord. 2014 Jun;29(7):949-53. doi: 10.1002/mds.25831. Epub 2014 Feb 14.

Clinical progression of SYNJ1-related early onset atypical parkinsonism: 3-year follow up of the original Italian family

Picillo M, Ranieri A, Orefice G, Bonifati V, Barone P.

J Neurol. 2014 Apr;261(4):823-4. doi: 10.1007/s00415-014-7270-6. Epub 2014 Feb 16.

[Neurological disorders and glaucoma - an overview]

Göbel K, Erb C.

Klin Monbl Augenheilkd. 2014 Feb;231(2):130-5. doi: 10.1055/s-0033-1360316. Epub 2014 Feb 15.

Practical approach to freezing of gait in Parkinson's disease

Okuma Y.

Pract Neurol. 2014 Aug;14(4):222-30. doi: 10.1136/practneurol-2013-000743. Epub 2014 Feb 14.

The dopamine D2 and adenosine A2A receptors: past, present and future trends for the treatment of Parkinson's disease

Jorg M, Scammells PJ, Capuano B.

Curr Med Chem. 2014;21(27):3188-210. doi: 10.2174/1389200215666140217110716.

Updated research and applications of small molecule inhibitors of Keap1-Nrf2 protein-protein interaction: a review

Zhuang C, Miao Z, Sheng C, Zhang W.

Curr Med Chem. 2014;21(16):1861-70. doi: 10.2174/0929867321666140217104648.

Phosphodiesterase as a new therapeutic target for the treatment of spinal cord injury and neurodegenerative diseases

Paterniti I, Esposito E, Cuzzocrea S.

Curr Med Chem. 2014;21(24):2830-8. doi: 10.2174/0929867321666140217102428.

Manic episode following deep brain stimulation of the subthalamic nucleus for Parkinson's disease: a case report

Ugurlu TT, Acar G, Karadag F, Acar F.

Turk Neurosurg. 2014;24(1):94-7. doi: 10.5137/1019-5149.JTN.7647-12.0.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias